The stock hit $23.26 in late trading, cooling from a $28.53 close earlier in the day. Management has yet to disclose the specific volume of shares to be offered or the target pricing for the round. Underwriters have been granted a 30-day window to purchase an additional 15% of the offering, a standard provision for such capital raises.
In section Market Quotes
Nuvectis Pharma Shares Slide on Planned Stock Offering
A 18% drop in after-hours trading greeted Nuvectis Pharma on Monday after the company announced its intent to launch an underwritten public stock offering. The decline follows a period of aggressive growth for the firm, which had seen its share value climb nearly fourfold since the beginning of the year.
Capital generated from the sale is earmarked for the advancement of the company’s drug development pipeline. This move represents a strategic pivot for the biotechnology firm as it seeks to translate its recent market momentum into sustained funding for its clinical research programs.
Comments (0)
No comments yet. Be the first!